Search Results

You are looking at 1 - 10 of 73 items for :

  • "Lung cancer screening" x
Clear All
Full access

Douglas E. Wood, Ella A. Kazerooni, Scott L. Baum, George A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Inga T. Lennes, Ann N.C. Leung, Samir S. Makani, Pierre P. Massion, Peter Mazzone, Robert E. Merritt, Bryan F. Meyers, David E. Midthun, Sudhakar Pipavath, Christie Pratt, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Peter B. Sachs, Matthew B. Schabath, Mark L. Schiebler, Betty C. Tong, William D. Travis, Benjamin Wei, Stephen C. Yang, Kristina M. Gregory and Miranda Hughes

these symptoms usually have advanced lung cancer. These facts—combined with the success of cervical, colon, and breast cancer screening—have been the impetus for developing an effective lung cancer screening (LCS) test. 8 – 10 Ideally, effective

Full access

Douglas E. Wood, George A. Eapen, David S. Ettinger, Lifang Hou, David Jackman, Ella Kazerooni, Donald Klippenstein, Rudy P. Lackner, Lorriana Leard, Ann N. C. Leung, Pierre P. Massion, Bryan F. Meyers, Reginald F. Munden, Gregory A. Otterson, Kimberly Peairs, Sudhakar Pipavath, Christie Pratt-Pozo, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Matthew B. Schabath, Lecia V. Sequist, Betty C. Tong, William D. Travis, Michael Unger and Stephen C. Yang

improving outcomes in cervical, colon, and breast cancers, have been the impetus for studies to develop an NCCN Clinical Practice Guidelines in Oncology for Lung Cancer Screening NCCN Categories of Evidence and Consensus Category 1: Based upon

Full access

Douglas E. Wood, Ella Kazerooni, Scott L. Baum, Mark T. Dransfield, George A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Ann N.C. Leung, Samir S. Makani, Pierre P. Massion, Bryan F. Meyers, Gregory A. Otterson, Kimberly Peairs, Sudhakar Pipavath, Christie Pratt-Pozo, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Peter B. Sachs, Matthew B. Schabath, Lecia V. Sequist, Betty C. Tong, William D. Travis, Stephen C. Yang, Kristina M. Gregory and Miranda Hughes

, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Lung Cancer Screening Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Lung Cancer Screening

Full access

Peter B. Bach

reinterpretation of the Mayo Lung Project randomized trial on lung cancer screening . Chest 1993 ; 103 ( Suppl 4 ): 337S – 341S . 5. Reich JM . Assessing the efficacy of lung cancer screening . Radiology 2006 ; 238 : 398 – 401 . 6

Full access

Jennifer A. Lewis, Heidi Chen, Kathryn E. Weaver, Lucy B. Spalluto, Kim L. Sandler, Leora Horn, Robert S. Dittus, Pierre P. Massion, Christianne L. Roumie and Hilary A. Tindle

, NCCN published the first lung cancer screening (LCS) guidelines. 4 US healthcare policy decisions have also been supportive, including the US Preventive Services Task Force (USPSTF) issuance of a grade B recommendation for annual LDCT in high

Full access

Douglas Arenberg and Ella A. Kazerooni

In November 2010, the National Lung Cancer Screening Trial (NLST) was halted by the NIH, with the compelling news that CT reduced lung cancer mortality by 20% and all-cause mortality by 7% when 3 annual low-dose helical CT scans were performed in

Full access

Douglas E. Wood

combined. Of course, lung cancer screening has been behind screening for other types of cancer for good reasons: concerns about the adverse unintended consequences of screening, including radiation exposure, false-positive diagnoses with unnecessary

Full access

Bernardo H. L. Goulart, Mark E. Bensink, David G. Mummy and Scott D. Ramsey

disease is rarely curable. Lung cancer screening tests can potentially reduce cancer mortality through detecting tumors at earlier stages, when treatments have higher chances of cure. 2 , 3 The NCI-sponsored National Lung Screening Trial (NLST) is the

Full access

Brady J. McKee, Shawn Regis, Andrea K. Borondy-Kitts, Jeffrey A. Hashim, Robert J. French Jr, Christoph Wald and Andrea B. McKee

generated controversy given the lack of formal evaluation in the NLST. 5 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening, v1.2012, recommended annual CTLS for 2 groups of high-risk individuals 1 : Group 1

Full access

The February 2012 article by Goulart et al titled, “Lung Cancer Screening With Low-Dose Computed Tomography: Costs, National Expenditures, and Cost-Effectiveness,” (J Natl Compr Canc Netw 2012, doi: 10.6004/jnccn.2012.0023 ) was published with an